Updating the metagenomics toolbox black canada dating
More than a decade later genomics is still big in business (and big business): the Obama administration announced in January 2015 that they intend to sequence one million human genomes (see Precision Medicine Initiative in the Other Internet Resources section below; see also Reardon 2015).
Craig Venter, the commercially minded nemesis of the publicly-funded HGP is also in the mix again, this time involved in a privately-funded collaboration that aims to sequence two million genomes over the course of the next ten years (Ledford 2016).
These three cases will highlight key issues that come up again and again in the context of genomics and postgenomics.
And equally important, we see not only the same players clash again but also the same promises being made, with talk of “groundbreaking health benefits” and “new medical breakthroughs” appearing once again in press releases and other announcements (see for instance Collins & Varmus 2015 or NIH 2015). For instance, China has emerged as a major player in the genomics field, with the BGI (formerly the Beijing Genomics Institute) already announcing in 2011 the aim to sequence one million genomes.
Moreover, DNA sequencing is no longer the only goal of these large-scale initiatives: the new genomics is of course still a genome-based effort, but it is a transformed enterprise that also focuses on data about proteins, DNA methylation patterns or the physiology and the environment of the people studied; DNA sequence data now forms only part of a much larger picture in the push for what is called ‘precision’ or ‘personalised’ medicine.